Clinical Trial Update: Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of virus-based gene therapy with AdV-HSV1-TK and AdV-Flt3L, combined with valacyclovir, for pediatric and young adult patients with resectable, re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasm
• Diffuse Hemispheric Glioma H3 G34-mutant
• Malignant Brain Neoplasm

Drugs mentioned

• AdV-Flt3L
• AdV-HSV1-TK
• Valacyclovir (Valacyclovir)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm | Phase 1 | Status: RECRUITING